Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma

Expert Opinion on Biological Therapy

Volumn 14, Issue 2, 2014, Pages 165-181

  Agrawal, Swati ^a   Townley, Robert G ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

Asthma; Bronchial hyper responsiveness; Corticosteroids; Dupilumab; Eosinophils; Exhaled nitric oxide; Interleukin 13; Lebrikizumab; Periostin; Pitrakinra

Indexed keywords

AMG 317; ANRUKINZUMAB; CORTICOSTEROID; DUPILUMAB; GSK 679586; IMA 026; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; LEBRIKIZUMAB; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 4; NITRIC OXIDE; PHOSPHODIESTERASE; PITRAKINRA; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRALOKINUMAB; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ASTHMA; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; EOSINOPHILIC ESOPHAGITIS; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FRACTIONAL EXHALED NITRIC OXIDE; GENE INDUCTION; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; LUNG INJURY; MEDIATOR; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIGNAL TRANSDUCTION; SKIN ALLERGY; SPUTUM; TH2 CELL; TISSUE INJURY;

ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; BRONCHI; CELL ADHESION MOLECULES; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; INFLAMMATION; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKINS; LUNG; NITRIC OXIDE; QUALITY OF LIFE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84891947803     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.859673     Document Type: Review

References (79)

1. Barnes PJ. New drugs for asthma. Semin Respir Crit Care Med 2012;33(6):685-94
2. Townley RG, Agrawal S, Sapkota K. Omalizumab for pediatric asthma. Expert Opin Biolog Ther 2010;10(11):1595-608
3. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18(5):716-25
4. Thomson NC, Chaudhuri R, Spears M. Emerging therapies for severe asthma BMC Med 2011;9:102
5. Poon AH, Eidelman DH, Martin JG, et al. Pathogenesis of severe asthma. Clin Exp Allergy 2012;42(5):625-37
6. O'Byrne PM, Naji N, Gauvreau GM. Severe asthma: future treatments. Clin Exp Allergy 2012;42(5):706-11
7. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science (New York, NY) 1998;282(5397):2258-61
8. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science (New York, NY) 1998;282(5397):2261-3
9. Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010;464(7293):1367-70
10. Arron JR, Scheerens H, Matthews JG. Redefining approaches to asthma: developing targeted biologic therapies. Adv Pharmacol (San Diego, Calif) 2013;66:1-49
11. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Curr Allergy Asthma Rep 2004;4(2):123-31
12. Krause S, Behrends J, Borowski A, et al. Blockade of interleukin-13- mediated cell activation by a novel inhibitory antibody to human IL-13 receptor alpha1. Mol Immunol 2006;43(11):1799-807
13. Townley RG. Interleukin 13 and the beta-adrenergic blockade theory of asthma revisited 40 years later. Ann Allergy Asthma Immunol 2007;99(3):215-24
14. Mitchell J, Dimov V, Townley RG. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. Curr Opin Investig Drugs 2010;11(5):527-34
15. Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and-12 in IL-13-induced inflammation and remodeling. J Clin Invest 2002;110(4):463-74
16. Townley RG, Sapkota M, Sapkota K. IL-13 and its genetic variants: effect on current asthma treatments. Discov Med 2011;12(67):513-23
17. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003;111(4):677-90; quiz 91
18. Kuperman DA, Huang X, Koth LL, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002;8(8):885-9
19. Ma B, Liu W, Homer RJ, et al. Role of CCR5 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2006;176(8):4968-78
20. Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008;121(3):685-91
21. Townley RG, Gendapodi PR, Qutna N, et al. Effect of interleukin 13 on bronchial hyperresponsiveness and the bronchoprotective effect of beta-adrenergic bronchodilators and corticosteroids. Ann Allergy Asthma Immunol 2009;102(3):190-7
22. Goleva E, Hauk PJ, Boguniewicz J, et al. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 2007;120(5):1065-72
23. Leung DY, Martin RJ, Szefler SJ, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med 1995;181(1):33-40
24. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373(9678):1905-17
25. Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006;174(2):134-41
26. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the national heart, lung, and blood institute's severe asthma research program. J Allergy Clin Immunol 2007;119(2):405-13
27. Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994;93(1):33-9
28. Leung DY, Spahn JD, Szefler SJ. Steroid-unresponsive asthma. Semin Respir Crit Care Med 2002;23(4):387-98
29. Yim RP, Koumbourlis AC. Steroid-resistant asthma. Paediatr Respir Rev 13(3):172-6; quiz 6-7
30. Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 1993;294(Pt 1):271-8
31. Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006;118(1):98-104
32. Tilman G, Mattiussi M, Brasseur F, et al. Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells. Mol Cancer 2007;6:80
33. Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 1999;14(7):1239-49
34. Li G, Oparil S, Sanders JM, et al. Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro. Atherosclerosis 2006;188(2):292-300
35. Snider P, Standley KN, Wang J, et al. Origin of cardiac fibroblasts and the role of periostin. Circ Res 2009;105(10):934-47
36. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 92(2):635-88
37. Gillan L, Matei D, Fishman DA, et al. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 2002;62(18):5358-64
38. Kudo Y, Siriwardena BS, Hatano H, et al. Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol 2007;22(10):1167-74
39. Sasaki H, Lo KM, Chen LB, et al. Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res 2001;92(8):869-73
40. Norris RA, Damon B, Mironov V, et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem 2007;101(3):695-711
41. Zhou HM, Wang J, Elliott C, et al. Spatiotemporal expression of periostin during skin development and incisional wound healing: lessons for human fibrotic scar formation. J Cell Commun Signal 2010;4(2):99-107
42. Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010;107(32):14170-5
43. Nishiyama T, Kii I, Kashima TG, et al. Delayed re-epithelialization in periostin-deficient mice during cutaneous wound healing. PLoS ONE 2011;6(4):e18410
44. Ontsuka K, Kotobuki Y, Shiraishi H, et al. Periostin, a matricellular protein, accelerates cutaneous wound repair by activating dermal fibroblasts. Exp Dermat 2012;21(5):331-6
45. Masuoka M, Shiraishi H, Ohta S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 2012;122(7):2590-600
46. Gordon ED, Sidhu SS, Wang ZE, et al. A protective role for periostin and TGF-beta in IgE-mediated allergy and airway hyperresponsiveness. Clin Exp Allergy 2012;42(1):144-55
47. Blanchard C, Mingler MK, McBride M, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 2008;1(4):289-96
48. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc NatL Acad Sci USA 2007;104(40):15858-63
49. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130(3):647-54; e10
50. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180(5):388-95
51. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. New Engl J Med 2011;365(12):1088-98
52. Thomson NC, Patel M, Smith AD. Lebrikizumab in the personalized management of asthm. Biologics 2012;6:329-35
53. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012;130(4):829-42; quiz 43-4
54. Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol 2013;425(8):1330-9
55. Mc Clintock et al. ATS abstract. Am J Resp Cric Care Med 2012;185:A3959
56. Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013;132(3):567-574.e12
57. Kasaian MT, Marquette K, Fish S, et al. An IL-4/IL-13 dual antagonist reduces lung inflammation, airway hyperresponsiveness, and ige production in mice. Am J Respir Cell Mol Biol 2013;49(1):37-46
58. Spiess C, Bevers J III, Jackman J, et al. Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J Biol Chem 2013;288(37):26583-93
59. Borish L. IL-4 and IL-13 dual antagonism: a promising approach to the dilemma of generating effective asthma biotherapeutics. Am J Respir Crit Care Med 2010;181(8):769-70
60. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels New Engl J Med 2013;368(26):2455-66
61. Piper E, Brightling C, Niven R, et al. A Phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013;41(2):330-8
62. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two Phase IIa studies. Lancet 2007;370(9596):1422-31
63. Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol 2012;130(2):516-22; e4
64. Lim S, Jatakanon A, John M, et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 1999;159(1):22-30
65. Mano K, Akbarzadeh A, Townley RG. Effect of hydrocortisone on beta-adrenergic receptors in lung membranes. Life Sci 1979;25(22):1925-30
66. Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol 1995;268(1 Pt 1):L41-6
67. Townley RG, Horiba M. Airway hyperresponsiveness: a story of mice and men and cytokines. Clin Rev Allergy Immunol 2003;24(1):85-110
68. Chibana K, Trudeau JB, Mustovich AT, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 2008;38(6):936-46
69. Jiang J, Malavia N, Suresh V, George SC. Nitric oxide gas phase release in human small airway epithelial cells. Respir Res 2009;10:3
70. Silkoff PE, Lent AM, Busacker AA, et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005;116(6):1249-55
71. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184(5):602-15
72. Wechsler ME. Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. New Engl J Med 2013;368(26):2511-13
73. Silkoff PE, Romero FA, Gupta N, et al. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 2004;113(4):e308-12
74. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18(2):254-61
75. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, Phase II study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181(8):788-96
76. Nino G, Hu A, Grunstein JS, et al. G Protein betagamma-subunit signaling mediates airway hyperresponsiveness and inflammation in allergic asthma. PLoS One 2012;7(2):e32078
77. Josephson MB, Jiao J, Xu S, et al. IL-13-induced changes in endogenous glucocorticoid metabolism in the lung regulate the proasthmatic response. Am J Physiol 2012;303(5):L382-90
78. Bartemes KR, Iijima K, Kobayashi T, et al. IL-33-responsive lineage-CD25+CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 2012;188(3):1503-13
79. Junttila IS, Watson C, Kummola L, et al. Efficient cytokine-induced IL-13 production by mast cells requires both IL-33 and IL-3. J Allergy Clin Immunol 2013;132(3):704-712.e10